Clinical trial
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
NCT07084558
Study timeline
Study start (actual)2025-08-13Date precision: day
Registry last updated2026-08-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Early and Locally Advanced Breast Cancerunresolved
Interventions
blood sample for Signatera (TM) testDIAGNOSTIC_TEST
biopsy for Ki-67 assessmentDIAGNOSTIC_TEST
FFPE tumor sample for Signatera (TM) test (archived)DIAGNOSTIC_TEST
Sponsors & collaborators
Austrian Breast & Colorectal Cancer Study Grouplead sponsor
Natera, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07084558 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.